Amazon Studios Orders Fourth Season of the Award-Winning Comedy The Marvelous Mrs. Maisel
13.12.2019 02:10:00 EET | Business Wire | Press release
(NASDAQ:AMZN) – Amazon Studios announced today that it has ordered a fourth season of the Emmy and Golden Globe-Award winning comedy The Marvelous Mrs. Maisel. The third season premiered Friday, Dec. 6 on Amazon Prime Video in more than 200 countries and territories worldwide. The Marvelous Mrs. Maisel received two Golden Globe nominations this week, for Best Television Series, Musical or Comedy, and for star Rachel Brosnahan for Best Performance by an Actress in a Series, Musical or Comedy.
“We were thrilled to hear that for the fourth time, we do not have to pack up and vacate the premises,” said Creator and Executive Producer Amy Sherman-Palladino and Executive Producer Daniel Palladino. “We’d like to thank Amazon for all their faith and support, their partnership and enthusiasm, and for letting us hang with our favorite people, the cast and crew of Maisel, for a little while longer.”
“The Marvelous Mrs. Maisel has been a worldwide phenomenon, and Season 3 has been no exception, with the series’ most watched opening weekend ever. We’re so happy that our Prime Video customers will get to see Midge’s story continue in Season 4,” said Jennifer Salke, Head of Amazon Studios. “Amy and Dan have created such funny, charming, relatable characters, all with their inimitable wit and eye for detail, and our customers around the world will be delighted to have another season in the world of The Marvelous Mrs. Maisel.”
In Season Three of The Marvelous Mrs. Maisel, Midge and Susie discover that life on tour with Shy is glamorous but humbling, and they learn a lesson about show business they’ll never forget. Joel struggles to support Midge while pursuing his own dreams, Abe embraces a new mission and Rose learns she has talents of her own.
The Marvelous Mrs. Maisel is the winner of sixteen Emmy Awards including Outstanding Comedy series, three Golden Globes including Best TV Series—Comedy, five Critics’ Choice Awards including Best Comedy Series, two PGA Awards, a WGA Award, and a Peabody Award.
The Marvelous Mrs. Maisel stars Emmy and Golden Globe winner Rachel Brosnahan, Golden Globe winner and four-time Emmy winner Tony Shalhoub, two-time Emmy winner Alex Borstein, Emmy nominee Marin Hinkle, Michael Zegen, Kevin Pollak, Caroline Aaron and Emmy winner Jane Lynch.
Prime members can stream The Marvelous Mrs. Maisel at www.amazon.com/Maisel Members can also download the series to mobile devices for offline viewing at no additional cost to their membership. The series is a global release and available on PrimeVideo.com for Prime Video members in more than 200 countries and territories. Watch where and when you want with the Prime Video app on your smart TV, mobile device, Fire TV, Fire tablet, Apple TV, Chromecast, game consoles, Comcast X1 or from the web. For a complete list of compatible devices, visit amazon.com/howtostream. Customers who are not already Prime members can sign up for a free trial at www.amazon.com/prime.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005869/en/
Contact information
Amazon.com, Inc.
Media Hotline
Amazon-pr@amazon.com
www.amazon.com/pr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom